Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL8507926 | 0.86 | MAPT (0.39) | CES1GAAMAPTNPC1RAB9A | |
| Carbamic Acid SCHEMBL28658378 | 0.85 | MAPT (0.38) | CES1GAAMAPTNPC1RAB9A | |
| Fumaric Acid SCHEMBL4504232 | 0.82 | ALDH1A1 (0.37) | GAAMAPTNPC1RAB9AHSD17B10 | |
| Maleic Acid SCHEMBL4504225 | 0.82 | ALDH1A1 (0.37) | GAAMAPTNPC1RAB9AHSD17B10 | |
| Citric Acid SCHEMBL164689 | 0.81 | ALDH1A1 (0.42) | MAPTHSD17B10TDP1 | |
| Cadaverine Tartrate SCHEMBL3996515 | 0.81 | GAA (0.34) | CES1GAAMAPTNPC1RAB9A | |
| Tartaric Acid SCHEMBL30548416 | 0.81 | GAA (0.34) | CES1GAAMAPTNPC1RAB9A | |
| Bromide SCHEMBL10654286 | 0.80 | GAA (0.46) | GAAMAPT | |
| Water SCHEMBL16465946 | 0.80 | GAA (0.46) | GAAMAPTNPC1RAB9AHSD17B10 | |
| SCHEMBL1787947 | 0.80 | GAA (0.46) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | CES1 842/4885GAA 1910/4885MAPT 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.